Tumor Acquisition for Biomarker Research in Lung Cancer

Stevenson, Marvaretta; Christensen, Jared; Shoemaker, Debra; Foster, Traci; Barry, William T.; Tong, Betty C.; Wahidi, Momen M.; Shofer, Scott; Datto, Michael B.; Ginsburg, Geoffrey S.; Crawford, Jeffrey; D’Amico, Thomas A.; Ready, Neal

doi:10.3109/07357907.2014.911880

Cited by 6 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could also contribute to the observed difference, since only 9% of our cryoconserved biopsies derived from patients receiving targeted treatments, and the main obstacle to rebiopsies was patient deterioration. Technically, however, our success rate was higher than 90% which is comparable to those reported by others (25) and with no major notable complications.…”

Section: Discussionsupporting

confidence: 87%

“…Only 56-68% of all samples exceeded the threshold value of 40%, 20% or 10%, which are considered adequate for gene expression, methylation or next-generation sequencing assays, respectively. These values were lower compared to a published study with a 70% success rate for microarray analyses (25). However, the authors did not mention the minimum tumor content used for microarray analyses.…”

Section: Discussionmentioning

confidence: 56%

“…Due to the preservation of several tissue aliquots in one biopsy procedure, we are able to perform molecular analyses even for most of those patients where the initial aliquot is inadequate. These observations have been made in a study where in 20% of the cases the second aliquot met the QC while the initial tissue specimen did not (25). Liquid biopsies are becoming increasingly part of routine diagnostics.…”

Section: Discussionmentioning

confidence: 98%

See 2 more Smart Citations

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives

Wessels

Muley

Christopoulos

et al. 2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Availability of tumor material at baseline and disease progression is increasingly important for patient management in non-small-cell lung cancer (NSCLC), especially for the application of targeted therapies like tyrosine kinase inhibitors and for immune checkpoint inhibitor treatment. Here we report the experience of prospective biomaterial acquisition in advanced NSCLC from a pilot project.Methods: Main objective was the longitudinal collection of high-quality, cryoconserved biopsies in addition to formalin-fixed paraffin-embedded (FFPE) biopsies required for routine diagnostics, along with blood samples and detailed clinical annotation using standardized questionnaires.Results: Over five years, 205 patients were enrolled for the project, yielding 387 cryoconserved biopsies and 1,098 serum, plasma and buffy-coat samples. The feasibility of obtaining the cryoconserved biopsies in addition to the FFPE biopsies was 89% for newly diagnosed cases, but dropped down to 56% and 47% at first and second disease progression, respectively. While forceps biopsy was the preferred procedure for tissue acquisition, the highest tissue amounts were received using the cryobiopsy method. Biopsies had a median tumor cellularity of 34% and yielded in median 13.6 µg DNA and 12 µg RNA (median RIN =8). During the five-year project, a maximum of 38 follow-up blood samples per patient were assembled in up to four therapy lines.Conclusions: Despite the poor condition and limited prognosis of most NSCLC patients, this serial biomaterial acquisition including routine collection of cryoconserved biopsies is feasible to support

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives

Wessels

Muley

Christopoulos

et al. 2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…Some studies have highlighted this issue and reported that only about 50% of tissue samples are adequate for biomarker testing. 13,29,30 Moreover, a study conducted by Ellis et al (2013) that investigated challenges in implementing EGFR testing in Canada identified inadequate diagnostic tissue for molecular testing as one of the major challenges. 31 An international survey conducted among oncologists showed that in addition to inadequate tissue, poor performance status and long turnaround time were the main reasons for not testing.…”

Section: ■■ Discussionmentioning

confidence: 99%

Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer

Shinde

Cao

Kothari

2016

JMCP

View full text Add to dashboard Cite

This study was sponsored by Merck & Co. Shinde is a study manager working for Merck under contract with AllSourcePPS, an Agile 1 company in Huntington Beach, California. Cao and Kothari are employees of Merck & Co., Kenilworth, New Jersey. Study concept and design were contributed primarily by Shinde and Kothari. Data analysis was performed by Cao. Data interpretation was performed by Shinde, Cao, and Kothari. Shinde wrote the manuscript with assistance from Cao and Kothari. The revision was completed primarily by Shinde and Kothari.

show abstract

“…Summarising, the dual-layer spectral CT system using the Z- effective images as lung biopsy guide might be helpful to provide more diagnostic samplings and biomarkers information in the era of patient-tailored therapy [ 21 , 22 ]. Obviously, clinical data will be necessary to support this hypothesis.…”

Section: Introductionmentioning

confidence: 99%

Dual-layer spectral CT fusion imaging for lung biopsies: more accurate targets, diagnostic samplings, and biomarker information?

et al. 2022

View full text Add to dashboard Cite

The increasingly widespread use of computed tomography (CT) has increased the number of detected lung lesions, which are then subjected to needle biopsy to obtain histopathological diagnosis. Obtaining high-quality biopsy specimens is fundamental for diagnosis and biomolecular characterisation that guide therapy decision-making. In order to obtain samples with high diagnostic potential, fusion imaging techniques, such as fusion between positron emission tomography and CT, have been introduced to target the biopsy where there more viable neoplastic cells can be sampled. Nowadays, dual-layer spectral CT represents a novel technology enabling an increased tissue characterisation. In particular, Z-effective images, i.e., colour-coded images based on the effective atomic number of tissue components, provide a higher level of discrimination than usual imaged based on x-ray attenuation in Hounsfield units and offer the potential of a better tissue characterisation. Our hypothesis is based on the future use of data provided by spectral CT, in particular by Z-effective images, as a guide for appropriate biopsy sampling for histopathological and biomolecular characterisation in the era of patient tailored-therapy.

show abstract

Tumor Acquisition for Biomarker Research in Lung Cancer

Cited by 6 publications

References 34 publications

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives

Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer

Dual-layer spectral CT fusion imaging for lung biopsies: more accurate targets, diagnostic samplings, and biomarker information?

Contact Info

Product

Resources

About